Markers of cardiac ischemia and inflammation

Cardiology Clinics

Volumn 23, Issue 4, 2005, Pages 491-501

  Wang, Tracy Y ^a   AlJaroudi, Wael A ^a   Newby, L Kristin ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALBUMIN; AMYLOID A PROTEIN; ATORVASTATIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CHOLINE; DARAPLADIB; FATTY ACID; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PRAVASTATIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; SELECTIN;

ARTERY THROMBOSIS; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 27644538771     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2005.08.007     Document Type: Review

References (89)

1. J.S. Alpert, K. Thygesen, and E. Antman Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction J Am Coll Cardiol 36 2000 959 969
2. A. Mantovani, F. Bussolino, and E. Dejana Cytokine regulation of endothelial cell function FASEB J 6 1992 2591 2599
3. P. Libby Molecular bases of the acute coronary syndromes Circulation 91 1995 2844 2850
4. E.P. Amento, N. Ehsani, and H. Palmer Cytokines and growth factors positive and negatively regular interstitial collagen gene expression in human vascular smooth muscle cells Arterioscler Thromb Vasc Biol 11 1991 1223 1230
5. Z.S. Galis, M. Muszynski, and G.K. Sukhova Cytokine stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion Circ Res 75 1994 181 189
6. Z.S. Galis, G.K. Sukhova, and M.W. Lark Increase expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 1994 2493 2503
7. P.R. Moreno, V.H. Bernardi, and J. Lopez-Cuellar Macrophages, smooth muscle cells, and tissue factor in unstable angina: Implications for cell-mediated thrombogenicity in acute coronary syndromes Circulation 94 1996 3090 3097
8. G. Neri Serneri, R. Abbate, and A. Gori Transient intermittent lymphocyte activation is responsible for the instability of angina Circulation 86 1992 790 797
9. S.D. Deodhar C-reactive protein: the best laboratory indicator available for monitoring disease activity Cleve Clin J Med 56 1989 126 130
10. E. Macy, T. Hayes, and R. Tracy Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference interval and epidemiologic applications Clin Chem 43 1997 52 58
11. C. Heeschen, C.W. Hamm, and J. Bruemmer Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial J Am Coll Cardiol 35 2000 1535 1542
12. D.A. Morrow, N. Rifai, and E.M. Antman C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11a substudy J Am Coll Cardiol 31 1998 1460
13. B. Lindahl, H. Toss, and A. Siegbahn Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease N Engl J Med 343 2000 1139 1147
14. S. James, P. Armstrong, and E. Barnathan Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV study J Am Coll Cardiol 41 2003 916 924
15. P. Ridker, N. Rifai, and M. Pfeffer Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels Circulation 98 1998 839 844
16. F. Haverkate, S.G. Thompson, and S.D. Pyke Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Lancet 349 1997 462 466
17. M.A. Mendall, P. Patel, and L. Ballam C-reactive protein and its relation to cardiovascular risk factors: a population base cross sectional study BMJ 1996 3-12:1061-5
18. L.H. Kuller, R.P. Tracy, and J. Shaten Relation of C-reactive protein and coronary heart disease in the MRFIT nested case control study. Multiple Risk Factor Intervention Trial Am J Epidemiol 144 1996 537 547
19. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979
20. W. Koenig, M. Sund, and M. Frohlich C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men Circulation 99 1999 237 242
21. P. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
22. P. Ridker, N. Rifai, and L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
23. P. Ridker, R. Glynn, and C. Hennekens C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 1998 2007 2011
24. P.M. Ridker High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 103 2001 1813 1818
25. M.C. Tataru, J. Heinrich, and R. Junker C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris Eur Heart J 21 2000 1000 1008
26. T. Masden, H.A. Skou, and V.E. Hansen C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease Am J Cardiol 88 2001 1139 1142
27. M.E. Hunt, P.G. O'Malley, and M.N. Vernalis C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis Am Heart J 141 2001 206 210
28. V. Pasceri, J. Willerson, and E. Yeh Direct pro-inflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
29. T. Zwaka, V. Homback, and J. Torzewski C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis Circulation 103 2001 1194 1197
30. S. Venugopal, S. Devaraj, and I. Yuhanna Demonstration that C-reactive protein decreases ENOS expression and bioactivity in human aortic endothelial cells Circulation 106 2002 1439 1441
31. J. Cermak, N.S. Key, and R.R. Bach C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor Blood 82 1993 513 520
32. G.J. Wolbink, M.C. Brouwer, and S. Buysmann CRP-mediated activation of complement in-vivo: assessment by measuring circulating complement-C-reactive protein complexes J Immunol 157 1996 473 479
33. S. Deveraj, D. Xu, and I. Jialal C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis Circulation 107 2003 398 404
34. C.J. Vaughan, M.B. Murphy, and B.M. Buckley Statins do more than just lower cholesterol Lancet 348 1996 1079 1082
35. R.S. Rosenson, and C.C. Tangney Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction JAMA 279 1998 1643 1650
36. P. Ridker, N. Rifai, and M. Pfeffer Long term effects of pravastatin on plasma concentration of C-reactive protein Circulation 100 1999 230 235
37. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
38. M.A. Albert, E. Danielson, and N. Rifai Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
39. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease - application to clinical and public health practice: a statement for healthcare professionals for the Center for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
40. B. Scheiffer, E. Scheiffer, and D. Hilfker-Kleiner Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability Circulation 101 2000 1372 1378
41. P. Ridker, N. Rifai, and M.J. Stampfer Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
42. E. Lindmark, E. Diderholm, and L. Wallentin Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease JAMA 286 2001 2107 2113
43. T. Hakkinen, J.S. Luoma, and M.O. Hiltunen Lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions Arterioscler Thromb Vasc Biol 19 1999 2909 2917
44. M.J. Caslake, C.J. Packard, and K.E. Suckling Lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase: a potential new risk factor for coronary artery disease Atherosclerosis 50 2000 413 419
45. C.J. Packard, D.S. O'Reilly, and M.J. Caslake Lipoprotein-associated phospholipase A2, as an independent predictor of coronary heart disease N Engl J Med 343 2000 1148 1155
46. G.J. Blake, N. Dada, and J.C. Fox A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women J Am Coll Cardiol 38 2001 1302 1306
47. C.M. Ballantyne, R.C. Hoogeveen, and H. Bang Lipoprotein-associated phospholipase A2, high sensitivity C-reactive protein, and risk for incident coronary heart disease in middle aged men and women in the Atherosclerosis Risk in Communities (ARIC) study Circulation 109 2004 837 842
48. E.S. Brilakis, J.P. McConnell, and R.J. Lennon Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up Eur Heart J 26 2005 137 144
49. C.A. Leach, D.M. Hickey, and R.J. Ife Lipoprotein-associated PLA2 inhibition-a novel, non-lipid lowering strategy for atherosclerosis therapy Farmaco 56 2001 45 50
50. V. Henn, J.R. Slupsky, and M. Grafe CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells Nature 351 1998 591 594
51. F. Mach, U. Schonbeck, and G.K. Sukhova Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis Proc Natl Acad Sci U S A 94 1997 1931 1936
52. U. Schonbeck, G.K. Sukhova, and K. Shimizu Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice Proc Natl Acad Sci U S A 97 2000 7456 7463
53. U. Schonbeck, N. Varo, and P. Libby Soluble CD40L and cardiovascular risk in women Circulation 103 2001 2266 2268
54. C. Heeschen, S. Dimmeler, and C. Hamm Soluble CD-40 ligand in acute coronary syndromes N Engl J Med 348 2003 1104 1111
55. A.J. Gearing, and W. Newman Circulating adhesion molecules in disease Immunol Today 14 1993 506 512
56. P. Ridker, C.H. Hennekens, and B. Roitman-Johnson Plasma concentration of soluble intracellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men Lancet 351 1998 88 92
57. P. Ridker, J.E. Buring, and N. Rifai Soluble P-selectin and the risk of future cardiovascular events Circulation 103 2001 491 495
58. S.J. Hwang, C.M. Ballantyne, and R. Sharrett Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities Study Circulation 96 1997 4219 4225
59. A. Artl, G. Marsche, and S. Lestavel Role of serum amyloid A during metabolism of acute phase HDL by macrophages Arterioscler Thromb Vasc Biol 20 2000 763 772
60. B.D. Johnson, K.E. Kip, and O.C. Marroquin Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women Circulation 109 2004 726 732
61. M. Girndt, and H. Kohler Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk Nephrol Dial Transplant 18 2003 1976 1979
62. J.H. Von der Thusen, J. Kuiper, and M.L. Fekkes Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice FASEB J 15 2001 2730 2732
63. D.A. Smith, S.D. Irving, and J. Sheldon Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina Circulation 104 2001 746 749
64. D. Bar-Or, E. Lau, and J.V. Winkler A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: A preliminary report J Emerg Med 19 2000 311 315
65. C.V. Pollack, and S. Sieck Use of ischemia-modified albumin in emergency department risk stratification of chest pain is both clinically effective and cost effective Ann Emerg Med Suppl 42 2003 S37
66. R.H. Christenson, S.H. Duh, and W.R. Sanhai Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: A multicenter study Clin Chem 47 2001 464 470
67. M.C. Kontos, S. Schorer, and J.D. Kirk Ischemia modified albumin, a new biomarker of myocardial ischemia, for the emergency diagnosis of acute coronary syndrome J Am Coll Cardiol 41 2003 340A
68. M. Panteghini Role and importance of biochemical markers in clinical cardiology Eur Heart J 25 2004 1187 1196
69. A.M. Kleinfeld, D. Prothro, and D.L. Brown Increases in serum unbound free fatty acid levels following coronary angioplasty Am J Cardiol 78 1996 1350 1354
70. B.C. Stein, and R.I. Levin Natriuretic peptides: physiology, therapeutic potential and risk stratification in ischemic heart disease Am Heart J 135 1998 914 923
71. T. Omland, A. Aakvaag, and V.V. Bonarjee Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide Circulation 93 1996 1963 1969
72. J.A. de Lamos, D.A. Morrow, and J.H. Bentley The prognostic value of B-type natriuretic peptide in acute coronary syndromes N Engl J Med 345 2001 1014 1021
73. S.K. James, B. Lindahl, and A. Seigbahn N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease Circulation 108 2003 275 281
74. S. Sadanandan, C.P. Cannon, and K. Chekuri Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction J Am Coll Cardiol 44 2004 564 568
75. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18 J Am Coll Cardiol 41 2003 1264 1272
76. T. Jernberg, B. Lindahl, and A. Siegbahn N terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis and the effect of invasive strategy in unstable coronary syndrome J Am Coll Cardiol 42 2003 1909
77. S. Talwar, I.B. Squire, and P.F. Downie Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina Heart 84 2000 421 424
78. K. Bibbins-Domingo, M. Ansari, and N.B. Schiller B-type natriuretic peptide and ischemia in patients with stable coronary disease Circulation 108 2003 2987 2992
79. K. Marumoto, M. Hamada, and K. Hiwada Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris Clin Sci 88 1995 551 556
80. Z.A. Kyriakides, M. Markianos, and L. Michalis Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty Clin Cardiol 23 2000 285
81. J. Tateishi, M. Masutani, and M. Ohyanagi Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty Clin Cardiol 23 2000 776 780
82. J.P. Goetze, A. Gore, and C.H. Moller Acute myocardial hypoxia increases BNP gene expression FASEB J 18 2004 1928 1930
83. S.P. D'Souza, D.M. Yellon, and C. Martin B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening Am J Physiol Heart Circ Physiol 284 2003 H1592 H1600
84. O. Danne, M. Mockel, and C. Lueders Prognostic implications of elevated whole blood choline levels in acute coronary syndromes Am J Cardiol 91 2003 1060 1067
85. K. Mizuno, K. Satomura, and A. Miyamoto Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes N Engl J Med 326 1992 287 291
86. A. Bayes-Genis, C.A. Conover, and M.T. Overgaard Pregnancy-associated plasma protein A as a marker of acute coronary syndromes N Engl J Med 345 2001 1022 1029
87. J. Lund, Q.P. Qin, and T. Ilva Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation Circulation 108 2003 1924 1926
88. S.M. Lynch, J.D. Morrow, and L.J. Roberts Formation of non-cyclooxygenase-derived prostanoids in plasma of low density lipoprotein exposed to oxidative stress in vitro J Clin Invest 93 1994 998 1004
89. P. Holvoet, D. Collen, and F. van de Werf Malondialdehyde-modified LDL as a marker of acute coronary syndromes JAMA 281 1999 1719 1721